Michael von Bergwelt-Baildon

39PUBLICATIONS
269CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Biomechanical engineeringHaematologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (39)

|Aug 24, 2026
TP53-mutant CHIP defines a pro-inflammatory phenotype and predicts adverse outcomes after CAR T-cell therapy.

|Aug 17, 2026
Real-world CAR-T practice patterns in patients with mantle cell lymphoma: an international survey on behalf of the EBMT lymphoma working party.

|Jul 01, 2026
Feasibility and safety of rapid glofitamab ramp-up.

|Jun 30, 2026
The HLH-Risk-Calculator is a machine learning-based tool to predict course & mortality of secondary hemophagocytic lymphohistiocytosis.

|Jun 01, 2026
TP53 deficiency in AML induces resistance to T-cell engagers through an immunosuppressive secretome.

|Feb 24, 2026
FLT3-directed BiTE molecules vs CAR T cells in AML: costimulatory signals mitigate T-cell exhaustion.

Lisa Rohrbacher, Daniel Nixdorf, Helena Stadler

Pageof 7

Frequent Collaborators

12 joint publications

Veit L Buecklein

10 joint publications

Kai Rejeski

6 joint publications

Michael D Jain

6 joint publications

Karsten Spiekermann